Loading organizations...
Loading organizations...
Aradigm Health: Healthcare platform enabling sustainable access to cell and gene therapies for payers, providers, manufacturers, and patients.
Aradigm Health is a public benefit corporation that builds a financial and delivery platform to enable sustainable access to high-cost cell and gene therapies, though its primary headquarters location remains undisclosed. The company operates an entirely pass-through financial and delivery model that creates specialized risk pools to provide cost predictability for employers, health plans, and healthcare providers while returning unspent funds. The organization partners with centers of excellence and pharmaceutical manufacturers while leveraging executive experience from major healthcare entities like Humana, UPMC, CVS, and CMS. To support its platform development and concierge patient operations, the enterprise recently secured $5 million in seed funding. This initial investment round was led by the prominent technology and healthcare venture capital firm Andreessen Horowitz. Aradigm Health was founded in 2024 by Dr. Will Shrank, Spencer Carrucciu, and Annie Collins.
Aradigm Health has raised $20.0M across 1 funding round.
Aradigm Health has raised $20.0M in total across 1 funding round.
Aradigm Health has raised $20.0M in total across 1 funding round.
Aradigm Health's investors include Frist Cressey Ventures, Andreessen Horowitz, Dan Mendelson.
Aradigm Health has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 10, 2025 | $20.0M Series A | Frist Cressey Ventures | Andreessen Horowitz, Dan Mendelson |